Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long‐term treatment in ZE and non‐ZE acid hypersecretors
Background: Helicobacter pylori infection may increase or decrease acid secretion and may augment proton pump inhibitor efficacy. Pepsin effects have not been reported. In Zollinger–Ellison syndrome (ZE) specifically, H. pylori has been reported to decrease acid. Aim: To examine H. pylori effects on...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2002-02, Vol.16 (2), p.303-313 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 313 |
|---|---|
| container_issue | 2 |
| container_start_page | 303 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 16 |
| creator | Hirschowitz, B. I. Simmons, J. Mohnen, J. |
| description | Background:
Helicobacter pylori infection may increase or decrease acid secretion and may augment proton pump inhibitor efficacy. Pepsin effects have not been reported. In Zollinger–Ellison syndrome (ZE) specifically, H. pylori has been reported to decrease acid.
Aim:
To examine H. pylori effects on secretion and dose of medication in hypersecretors (basal acid output > 15 mmol/h) undergoing long‐term treatment with individually optimized lansoprazole doses.
Methods:
Sixty‐five patients (47 ZE and 18 non‐ZE), treated for > 3 months to 10 years, were tested every 6 months with endoscopy, gastric analysis and serum gastrin.
Results:
Forty‐three per cent were H. pylori‐positive. Acid, pepsin and gastrin were not different between H. pylori‐positive and H. pylori‐negative patients before or during long‐term lansoprazole treatment. Initially, H. pylori‐positive patients required less lansoprazole than H. pylori‐negative patients (68 ± 6 vs. 96 ± 8 mg/day), but after 3 years the doses converged (83 vs. 86 mg/day). The disappearance of H. pylori in 15 patients caused no significant changes in acid, pepsin, gastrin or lansoprazole dose in the following 4 years.
Conclusions:
H. pylori had no significant initial or long‐term physiological or potential clinical effects on acid or pepsin secretion or gastrin in these acid hypersecretors. |
| doi_str_mv | 10.1046/j.1365-2036.2002.01175.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71475836</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71475836</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4455-f95502a10117c7dff3ee612fd58126ba9ff6f175a9638b39b77f753975cb6bc3</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhS1ERYfCKyBvYJdgx7GdLFhUVUuRispiVmwsx7kePHLsYGdEh1UfgVUfsE9C0hnRLSv_3O8c-96DEKakpKQWH7clZYIXFWGirAipSkKp5OXdC7T6V3iJVqQSbVE1lJ2i1zlvCSFCkuoVOqW0EaSm9Qo9fHUhJgzWgpkyjhZfg3cmdtpMkPC49zE5HAPe6DwlZ3AGk2By840OPe5jhkXkdchxTPp39ID7XXJhg30Mm8f7P7PNgKcEehogTNgF_P3ySRtimMvLwbge_9iPkA7mMeU36MRqn-HtcT1D66vL9cV1cXP7-cvF-U1h6przwrack0rTpX0je2sZgKCV7XlDK9Hp1lph58noVrCmY20npZWctZKbTnSGnaEPB9sxxZ87yJMaXDbg53Yg7rKStJa8YWIGmwNoUsw5gVVjcoNOe0WJWiJRW7VMXi2TV0sk6ikSdTdL3x3f2HUD9M_CYwYz8P4I6Gy0t0kH4_Izx9pGNFzO3KcD98t52P_3B9T5t_WyY38BPQOrqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71475836</pqid></control><display><type>article</type><title>Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long‐term treatment in ZE and non‐ZE acid hypersecretors</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Hirschowitz, B. I. ; Simmons, J. ; Mohnen, J.</creator><creatorcontrib>Hirschowitz, B. I. ; Simmons, J. ; Mohnen, J.</creatorcontrib><description>Background:
Helicobacter pylori infection may increase or decrease acid secretion and may augment proton pump inhibitor efficacy. Pepsin effects have not been reported. In Zollinger–Ellison syndrome (ZE) specifically, H. pylori has been reported to decrease acid.
Aim:
To examine H. pylori effects on secretion and dose of medication in hypersecretors (basal acid output > 15 mmol/h) undergoing long‐term treatment with individually optimized lansoprazole doses.
Methods:
Sixty‐five patients (47 ZE and 18 non‐ZE), treated for > 3 months to 10 years, were tested every 6 months with endoscopy, gastric analysis and serum gastrin.
Results:
Forty‐three per cent were H. pylori‐positive. Acid, pepsin and gastrin were not different between H. pylori‐positive and H. pylori‐negative patients before or during long‐term lansoprazole treatment. Initially, H. pylori‐positive patients required less lansoprazole than H. pylori‐negative patients (68 ± 6 vs. 96 ± 8 mg/day), but after 3 years the doses converged (83 vs. 86 mg/day). The disappearance of H. pylori in 15 patients caused no significant changes in acid, pepsin, gastrin or lansoprazole dose in the following 4 years.
Conclusions:
H. pylori had no significant initial or long‐term physiological or potential clinical effects on acid or pepsin secretion or gastrin in these acid hypersecretors.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1046/j.1365-2036.2002.01175.x</identifier><identifier>PMID: 11860414</identifier><language>eng</language><publisher>Oxford UK: Blackwell Science Ltd</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles ; Adult ; Anti-Ulcer Agents - administration & dosage ; Anti-Ulcer Agents - therapeutic use ; Biological and medical sciences ; Digestive system ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Gastric Acid - metabolism ; Gastrins - blood ; Gastroenterology. Liver. Pancreas. Abdomen ; Helicobacter Infections - complications ; Helicobacter Infections - drug therapy ; Helicobacter pylori - drug effects ; Humans ; Lansoprazole ; Male ; Medical sciences ; Middle Aged ; Omeprazole - administration & dosage ; Omeprazole - analogs & derivatives ; Omeprazole - therapeutic use ; Other diseases. Semiology ; Pepsin A - metabolism ; Pharmacology. Drug treatments ; Prospective Studies ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Zollinger-Ellison Syndrome - complications ; Zollinger-Ellison Syndrome - drug therapy ; Zollinger-Ellison Syndrome - pathology</subject><ispartof>Alimentary pharmacology & therapeutics, 2002-02, Vol.16 (2), p.303-313</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4455-f95502a10117c7dff3ee612fd58126ba9ff6f175a9638b39b77f753975cb6bc3</citedby><cites>FETCH-LOGICAL-c4455-f95502a10117c7dff3ee612fd58126ba9ff6f175a9638b39b77f753975cb6bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2036.2002.01175.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2036.2002.01175.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13986857$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11860414$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hirschowitz, B. I.</creatorcontrib><creatorcontrib>Simmons, J.</creatorcontrib><creatorcontrib>Mohnen, J.</creatorcontrib><title>Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long‐term treatment in ZE and non‐ZE acid hypersecretors</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Background:
Helicobacter pylori infection may increase or decrease acid secretion and may augment proton pump inhibitor efficacy. Pepsin effects have not been reported. In Zollinger–Ellison syndrome (ZE) specifically, H. pylori has been reported to decrease acid.
Aim:
To examine H. pylori effects on secretion and dose of medication in hypersecretors (basal acid output > 15 mmol/h) undergoing long‐term treatment with individually optimized lansoprazole doses.
Methods:
Sixty‐five patients (47 ZE and 18 non‐ZE), treated for > 3 months to 10 years, were tested every 6 months with endoscopy, gastric analysis and serum gastrin.
Results:
Forty‐three per cent were H. pylori‐positive. Acid, pepsin and gastrin were not different between H. pylori‐positive and H. pylori‐negative patients before or during long‐term lansoprazole treatment. Initially, H. pylori‐positive patients required less lansoprazole than H. pylori‐negative patients (68 ± 6 vs. 96 ± 8 mg/day), but after 3 years the doses converged (83 vs. 86 mg/day). The disappearance of H. pylori in 15 patients caused no significant changes in acid, pepsin, gastrin or lansoprazole dose in the following 4 years.
Conclusions:
H. pylori had no significant initial or long‐term physiological or potential clinical effects on acid or pepsin secretion or gastrin in these acid hypersecretors.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles</subject><subject>Adult</subject><subject>Anti-Ulcer Agents - administration & dosage</subject><subject>Anti-Ulcer Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Digestive system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Gastric Acid - metabolism</subject><subject>Gastrins - blood</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Helicobacter Infections - complications</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter pylori - drug effects</subject><subject>Humans</subject><subject>Lansoprazole</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Omeprazole - administration & dosage</subject><subject>Omeprazole - analogs & derivatives</subject><subject>Omeprazole - therapeutic use</subject><subject>Other diseases. Semiology</subject><subject>Pepsin A - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Zollinger-Ellison Syndrome - complications</subject><subject>Zollinger-Ellison Syndrome - drug therapy</subject><subject>Zollinger-Ellison Syndrome - pathology</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAUhS1ERYfCKyBvYJdgx7GdLFhUVUuRispiVmwsx7kePHLsYGdEh1UfgVUfsE9C0hnRLSv_3O8c-96DEKakpKQWH7clZYIXFWGirAipSkKp5OXdC7T6V3iJVqQSbVE1lJ2i1zlvCSFCkuoVOqW0EaSm9Qo9fHUhJgzWgpkyjhZfg3cmdtpMkPC49zE5HAPe6DwlZ3AGk2By840OPe5jhkXkdchxTPp39ID7XXJhg30Mm8f7P7PNgKcEehogTNgF_P3ySRtimMvLwbge_9iPkA7mMeU36MRqn-HtcT1D66vL9cV1cXP7-cvF-U1h6przwrack0rTpX0je2sZgKCV7XlDK9Hp1lph58noVrCmY20npZWctZKbTnSGnaEPB9sxxZ87yJMaXDbg53Yg7rKStJa8YWIGmwNoUsw5gVVjcoNOe0WJWiJRW7VMXi2TV0sk6ikSdTdL3x3f2HUD9M_CYwYz8P4I6Gy0t0kH4_Izx9pGNFzO3KcD98t52P_3B9T5t_WyY38BPQOrqw</recordid><startdate>200202</startdate><enddate>200202</enddate><creator>Hirschowitz, B. I.</creator><creator>Simmons, J.</creator><creator>Mohnen, J.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200202</creationdate><title>Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long‐term treatment in ZE and non‐ZE acid hypersecretors</title><author>Hirschowitz, B. I. ; Simmons, J. ; Mohnen, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4455-f95502a10117c7dff3ee612fd58126ba9ff6f175a9638b39b77f753975cb6bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles</topic><topic>Adult</topic><topic>Anti-Ulcer Agents - administration & dosage</topic><topic>Anti-Ulcer Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Digestive system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Gastric Acid - metabolism</topic><topic>Gastrins - blood</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Helicobacter Infections - complications</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter pylori - drug effects</topic><topic>Humans</topic><topic>Lansoprazole</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Omeprazole - administration & dosage</topic><topic>Omeprazole - analogs & derivatives</topic><topic>Omeprazole - therapeutic use</topic><topic>Other diseases. Semiology</topic><topic>Pepsin A - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Zollinger-Ellison Syndrome - complications</topic><topic>Zollinger-Ellison Syndrome - drug therapy</topic><topic>Zollinger-Ellison Syndrome - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hirschowitz, B. I.</creatorcontrib><creatorcontrib>Simmons, J.</creatorcontrib><creatorcontrib>Mohnen, J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hirschowitz, B. I.</au><au>Simmons, J.</au><au>Mohnen, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long‐term treatment in ZE and non‐ZE acid hypersecretors</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2002-02</date><risdate>2002</risdate><volume>16</volume><issue>2</issue><spage>303</spage><epage>313</epage><pages>303-313</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Background:
Helicobacter pylori infection may increase or decrease acid secretion and may augment proton pump inhibitor efficacy. Pepsin effects have not been reported. In Zollinger–Ellison syndrome (ZE) specifically, H. pylori has been reported to decrease acid.
Aim:
To examine H. pylori effects on secretion and dose of medication in hypersecretors (basal acid output > 15 mmol/h) undergoing long‐term treatment with individually optimized lansoprazole doses.
Methods:
Sixty‐five patients (47 ZE and 18 non‐ZE), treated for > 3 months to 10 years, were tested every 6 months with endoscopy, gastric analysis and serum gastrin.
Results:
Forty‐three per cent were H. pylori‐positive. Acid, pepsin and gastrin were not different between H. pylori‐positive and H. pylori‐negative patients before or during long‐term lansoprazole treatment. Initially, H. pylori‐positive patients required less lansoprazole than H. pylori‐negative patients (68 ± 6 vs. 96 ± 8 mg/day), but after 3 years the doses converged (83 vs. 86 mg/day). The disappearance of H. pylori in 15 patients caused no significant changes in acid, pepsin, gastrin or lansoprazole dose in the following 4 years.
Conclusions:
H. pylori had no significant initial or long‐term physiological or potential clinical effects on acid or pepsin secretion or gastrin in these acid hypersecretors.</abstract><cop>Oxford UK</cop><pub>Blackwell Science Ltd</pub><pmid>11860414</pmid><doi>10.1046/j.1365-2036.2002.01175.x</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2002-02, Vol.16 (2), p.303-313 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71475836 |
| source | MEDLINE; Access via Wiley Online Library; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles Adult Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - therapeutic use Biological and medical sciences Digestive system Dose-Response Relationship, Drug Drug Administration Schedule Female Gastric Acid - metabolism Gastrins - blood Gastroenterology. Liver. Pancreas. Abdomen Helicobacter Infections - complications Helicobacter Infections - drug therapy Helicobacter pylori - drug effects Humans Lansoprazole Male Medical sciences Middle Aged Omeprazole - administration & dosage Omeprazole - analogs & derivatives Omeprazole - therapeutic use Other diseases. Semiology Pepsin A - metabolism Pharmacology. Drug treatments Prospective Studies Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Zollinger-Ellison Syndrome - complications Zollinger-Ellison Syndrome - drug therapy Zollinger-Ellison Syndrome - pathology |
| title | Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long‐term treatment in ZE and non‐ZE acid hypersecretors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T23%3A04%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Minor%20effects%20of%20Helicobacter%20pylori%20on%20gastric%20secretion%20and%20dose%20of%20lansoprazole%20during%20long%E2%80%90term%20treatment%20in%20ZE%20and%20non%E2%80%90ZE%20acid%20hypersecretors&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Hirschowitz,%20B.%20I.&rft.date=2002-02&rft.volume=16&rft.issue=2&rft.spage=303&rft.epage=313&rft.pages=303-313&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1046/j.1365-2036.2002.01175.x&rft_dat=%3Cproquest_cross%3E71475836%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71475836&rft_id=info:pmid/11860414&rfr_iscdi=true |